ClinicalTrials.gg
CompletedNCT04737447WBVTUpdated Dec 9, 2024

Whole Body Vibration Training in the Treatment for Children's Incontinence - a Randomized-Controlled Trial

An interventional study of Whole Body Vibration Training in Incontinence, Urinary, sponsored by University Children's Hospital, Zurich. Completed at 1 site in Switzerland. Open to participants aged 7 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by University Children's Hospital, Zurich · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Jan 2019, registered Dec 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
7 Years to 16 Years
Sex
All
01

Study summary

The determined study category is a prospective clinical randomized controlled study to evaluate the effect of WBVT in combination with urophysiotherapy to playfully expand the therapeutic options for children and adolescents with incontinence. This will be the first time use of WBVT for treating incontinence in children.

Read the detailed description

Approximately up to 20% of children suffer from urinary incontinence. These children and frequently their families are emotionally and behaviourally affected which in turn leads to psychological distress. Urophysiotherapy became one of the first line treatments for children with urinary incontinence. Urophysiotherapy includes pelvic floor muscles training (PFMT), a treatment method not easily applicable in children. We therefore supplement the standard training with WBVT which is already evaluated in the adult population to improve the strength of the muscles of the pelvic floor. With the medical device of Galileo® children are able to train the pelvic muscles automatically and playfully.The primary objective is to investigate the effect of WBVT on children's incontinence measured by validated incontinence scores (DVISS, RUIS). The secondary objective is to evaluate the effect on the bladder function (uroflowmetry, residual urine).The primary outcome is to significantly improve incontinence symptoms by using WBVT in combination with urophysiotherapy for 9 weeks measured by incontinence scores.I nclusion criteria

  • Male and Female participants 7-16 years of age
  • Daytime incontinence (> 6 months)
  • Written informed consent by the participant after information about the research project Exclusion criteria
  • Neurogenic bladder dysfunction
  • Congenital anomalies of the urinary tract
  • Patients who already take part in another study concerning treating incontinence 30 days before and after participation in this study
  • Patients with incontinence, who already underwent urophysiotherapy
  • Medication for treating incontinence

    • Contraindications for the use of Galileo®: epilepsy, acute fractures, urolithiasis, cholecystolithaisis, after recent surgery, acute hernia, arthritis, thrombosis, rheumatic diseases, acute discopathy, patients with implants diabetes or pregnancy.
  • Patients and parents without any motivation for urophysiotherapy
  • Patients who neither mentally nor physically are able to pursue urophysiotherapy

In this randomized controlled trial children with incontinence will be randomly assigned in two groups: an "urophysiotherapy plus WBVT" group and a control group receiving urophysiotherapy only. The children will be treated in both groups according to a standardized protocol for 9 weeks. In addition to clinical investigations and urodynamic studies two different incontinence scores (DVISS and RUIS) will be used to determine the severity of incontinence at the time of diagnosis, at the end of the therapy (12 weeks after assessment), 24 and at 48 weeks after assessment. To determine the effect of WBVT the results will be compared using the Student's t-test and the Mann-Whitney U test.

02

Conditions studied

  • Incontinence, Urinary

Keywords

  • Whole Body Vibration Training (WBVT)
  • Incontinence in children
03

In context

Urinary Incontinence

1,375 studies on the registry are indexed under Urinary Incontinence; 224 are open to participants now.

This study's enrollment of 40 is below the median of 66 across 1,021 interventional studies indexed under Urinary Incontinence.

Browse Urinary Incontinence studies →

Lead sponsor

University Children's Hospital, Zurich is the lead sponsor of 95 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Female participants 7-16 years of age
  • Daytime incontinence (> 6 months)
  • Written informed consent by the participant after information about the research project

Exclusion criteria

Exclusion Criteria:

  • Neurogenic bladder dysfunction
  • Congenital anomalies of the urinary tract
  • Patients who already take part in another study concerning treating incontinence 30 days before and after participation in this study
  • Patients with incontinence, who already underwent urophysiotherapy
  • Medication for treating incontinence
  • Contraindications for the use of Galileo®: epilepsy, acute fractures, urolithiasis, cholecystolithaisis, after recent surgery, acute hernia, arthritis, thrombosis, rheumatic diseases, acute discopathy, patients with implants diabetes or pregnancy.
  • Patients and parents without any motivation for urophysiotherapy
  • Patients who neither
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    Group A (Control Group)

    20 participants treated with standardized urophysiotherapy twice a week, once for 45 Minutes and then for 15 Minutes. Urophysiotherapy is a well manifested and standardized therapy in the treatment für children's incontinence after the age of five years.

    Device: Whole Body Vibration Training

  • Active comparator
    Group B (Study Group)

    20 participants treated with standardized urophysiotherapy and Whole Body Vibration training (WBVT). These patients are treated with the standardized urophysiotherapy once a week and furthermore they train with WBVT twice a week for each time 15 minutes. Criteria for modifying the device utilization are based on participant's age and therapy progress. The utilized frequency of the device is individually adapted to the participant. Older patients (\> ten years old) are allowed to higher frequency standards than younger participants (\< 10 years old). The amplitude (0.5 mm - 2 mm) is alternated to the participant's age and height. If side effects occur (e.g. dizziness), frequency can be alternated. The intended frequency level is between 10 an 20 Hz.

    Device: Whole Body Vibration Training

Interventions

  • DeviceWhole Body Vibration Training

    Galileo® Trainer is a vibration board. The movement alternating to different sides during walking correlates with the movement on the board due to variable amplitudes and frequencies. Movements of the vibration board are quickly changing and thus simulating the tilting movements of the pelvic during walking but with higher frequency. Muscles of legs and core are activated reflexively. In our study there are performed static practices and pelvic activating practices. Each physiotherapist is experienced in the technical and practical handling of the device.

    Also known as: Galileo Training

06

What researchers measure

Primary outcomes

  1. Change of Dysfunctional Voiding and Incontinence Score (DVISS)

    Incontinence score for children.This statistically validated functional voiding problems symptom score may provide accurate, objective and scientific bases to grade the symptoms in comparative research, diagnosis, treatment and followup of patients with wetting and functional voiding disorders. It contains 13 questions. The following applies: A child is continent when score is \< 9 points and therefore responding to the therapy. Score decrease more than 30% means partial responding. Score decrease less than 30% means the failure of therapy.

    Time frame: Change of DVISS between Baseline and Post-interventional at 12 weeks after Beginning of Intervention, 24 and 48 weeks after Intervention

  2. Change of Revised Urinary Incontinence Scale (RUIS)

    Incontinence Score for adults.The RUIS is a short, reliable and valid five item scale that can be used to assess urinary incontinence and to monitor patient outcomes following treatment. The following applies: Incontinence is mild if scoring is less than 4, incontinence is moderate if scoring is between 4 and 8 and severe if it is more than 13.

    Time frame: Change of RUIS between Baseline and post-interventional (12 weeks after Beginning of Intervention, 24 and 48 weeks after Intervention)

Secondary outcomes

  1. Change of Urinary flow measurements (UF)

    Urinary flow rate assessment is a basic noninvasive urodynamic test that is widely used to distinguish micturition problems. Key parameters are maximal flow rate (Qmax), voided volume, and flow pattern. Uroflowmetry parameters should ideally be evaluated when the voided volume is \> 150 mL. The diagnostic accuracy of uroflowmetry for detecting bladder outlet obstruction varies considerably and is substantially influenced by diagnostic threshold values. Low Qmax can arise as a consequence of bladder outlet obstruction, detrusor underactivity, or an underfilled bladder.

    Time frame: Change of UF between Baseline and post-interventional (12 weeks after Beginning of Intervention, 24 and 48 weeks after Intervention)

  2. Change of Postvoid residual urine (PVR)

    Postvoid residual urine (PVR) is the amount of urine retained in the bladder after a voluntary void and functions as a diagnostic tool. In our study, it is measured by bladder scan after urinary flow measurement to detect how much urine is left in the bladder.

    Time frame: Change of PVR between Baseline and post-interventional (12 weeks after Beginning of Intervention, 2 weeks after Beginning of Intervention, 24 and 48 weeks after Intervention)

07

Study locations

1 site
  • University Children's Hospital
    Zurich, 8032, Switzerland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Jan 2023, 48 months.

Of 423 non-industry interventional studies with no phase under Urinary Incontinence, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 39. This study's 48 months is above that.

Counting every sponsor, half of 515 studies reached it within 16 months; a quarter within 7 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2020
First posted
Feb 3, 2021
StartActual
Jan 15, 2019
Primary completionActual
Jan 31, 2023
CompletionActual
Jan 31, 2023
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04737447
Lead sponsor
University Children's Hospital, Zurich
Responsible party
Alice Hoelscher (Dr. med. Alice Catherine Hoelscher, University Children's Hospital, Zurich) — Principal investigator
First posted
Feb 3, 2021
Start date
Jan 15, 2019
Primary completion
Jan 31, 2023
Completion
Jan 31, 2023
Last update
Dec 9, 2024

Study contacts

Hoelscher
principal investigator · Consultant in Pediatric Urology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion